Moleculin Biotech, Inc. (MBRX)
0.77
+0.02
(+2.65%)
USD |
NASDAQ |
Sep 09, 15:06
Moleculin Biotech Total Assets (Quarterly) : 21.09M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 21.09M |
| March 31, 2026 | 23.36M |
| December 31, 2025 | 22.13M |
| September 30, 2025 | 20.35M |
| June 30, 2025 | 21.59M |
| March 31, 2025 | 21.01M |
| December 31, 2024 | 16.92M |
| September 30, 2024 | 16.92M |
| June 30, 2024 | 25.58M |
| March 31, 2024 | 30.84M |
| December 31, 2023 | 38.22M |
| September 30, 2023 | 39.52M |
| June 30, 2023 | 47.12M |
| March 31, 2023 | 51.06M |
| December 31, 2022 | 57.42M |
| September 30, 2022 | 65.37M |
| June 30, 2022 | 73.26M |
| March 31, 2022 | 78.80M |
| December 31, 2021 | 84.09M |
| September 30, 2021 | 88.70M |
| June 30, 2021 | 93.54M |
| March 31, 2021 | 99.78M |
| Date | Value |
|---|---|
| December 31, 2020 | 29.16M |
| September 30, 2020 | 27.14M |
| June 30, 2020 | 31.38M |
| March 31, 2020 | 25.47M |
| December 31, 2019 | 25.24M |
| September 30, 2019 | 30.40M |
| June 30, 2019 | 31.85M |
| March 31, 2019 | 21.30M |
| December 31, 2018 | 19.58M |
| September 30, 2018 | 20.90M |
| June 30, 2018 | 24.07M |
| March 31, 2018 | 24.93M |
| December 31, 2017 | 19.48M |
| September 30, 2017 | 20.63M |
| June 30, 2017 | 21.25M |
| March 31, 2017 | 20.32M |
| December 31, 2016 | 16.39M |
| September 30, 2016 | 17.58M |
| June 30, 2016 | 18.74M |
| March 31, 2016 | 0.2927M |
| December 31, 2015 | 0.0311M |
| September 30, 2015 | 0.1057M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 9.50M |
| Shareholders Equity (Quarterly) | 11.59M |
| Debt to Equity Ratio | 0.0252 |
| Current Ratio | 0.9366 |
| Net Debt Paydown Yield | 0.16% |